In prostate cancer patients, using quantitative SPECT at ~ 48 h after 177Lu-PSMA-I&T RPT, we found that body habitus and renal function were both significantly and negatively correlated with specific absorbed dose estimates for the bone marrow and the kidney [14]. The gene discussed is FOLH1; the disease is prostate carcinoma.